LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,089
تعداد مقالات9,995
تعداد مشاهده مقاله26,175,875
تعداد دریافت فایل اصل مقاله7,235,704
Bamneshin, Khadijeh, Rabi Mahdavi, Seied, Bitarafan-Rajabi, Ahmad, Geramifar, Parham, Hejazi, Payman, Koosha, Fereshteh, Jadidi, Majid. (1401). Evaluation of Dose-Painting in the Dominant Intraprostatic Lesions by Radiobiological Parameters using 68Ga- PSMA PET/CT. سامانه مدیریت نشریات علمی, 12(4), 369-376. doi: 10.31661/jbpe.v0i0.1912-1006
Khadijeh Bamneshin; Seied Rabi Mahdavi; Ahmad Bitarafan-Rajabi; Parham Geramifar; Payman Hejazi; Fereshteh Koosha; Majid Jadidi. "Evaluation of Dose-Painting in the Dominant Intraprostatic Lesions by Radiobiological Parameters using 68Ga- PSMA PET/CT". سامانه مدیریت نشریات علمی, 12, 4, 1401, 369-376. doi: 10.31661/jbpe.v0i0.1912-1006
Bamneshin, Khadijeh, Rabi Mahdavi, Seied, Bitarafan-Rajabi, Ahmad, Geramifar, Parham, Hejazi, Payman, Koosha, Fereshteh, Jadidi, Majid. (1401). 'Evaluation of Dose-Painting in the Dominant Intraprostatic Lesions by Radiobiological Parameters using 68Ga- PSMA PET/CT', سامانه مدیریت نشریات علمی, 12(4), pp. 369-376. doi: 10.31661/jbpe.v0i0.1912-1006
Bamneshin, Khadijeh, Rabi Mahdavi, Seied, Bitarafan-Rajabi, Ahmad, Geramifar, Parham, Hejazi, Payman, Koosha, Fereshteh, Jadidi, Majid. Evaluation of Dose-Painting in the Dominant Intraprostatic Lesions by Radiobiological Parameters using 68Ga- PSMA PET/CT. سامانه مدیریت نشریات علمی, 1401; 12(4): 369-376. doi: 10.31661/jbpe.v0i0.1912-1006

Evaluation of Dose-Painting in the Dominant Intraprostatic Lesions by Radiobiological Parameters using 68Ga- PSMA PET/CT

Journal of Biomedical Physics and Engineering
مقاله 6، دوره 12، شماره 4، مهر و آبان 2022، صفحه 369-376    اصل مقاله (744.59 K)
نوع مقاله: Original Research
شناسه دیجیتال (DOI): 10.31661/jbpe.v0i0.1912-1006
نویسندگان
Khadijeh Bamneshin1، 2؛ Seied Rabi Mahdavi3؛ Ahmad Bitarafan-Rajabi* 4؛ Parham Geramifar5؛ Payman Hejazi6؛ Fereshteh Koosha7؛ Majid Jadidi6
1PhD, Department of Medical Physics, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2PhD, Student Research Committee, Iran University of Medical Sciences, Tehran, Iran
3PhD, Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran
4PhD, Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
5PhD, Department of Nuclear Medicine, Shariati Hospital Tehran University of Medical Sciences, Tehran, Iran
6PhD, Department of Medical Physics, Faculty of Medicine, Semnan University of Medical Sciences, Semnan, Iran
7PhD, Department of Radiology Technology, Faculty of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
چکیده
Background: Patients diagnosed with dominant intraprostatic lesions (DIL) may need radiation doses over than 80 Gy. Dose-painting by contours (DPC) is a useful technique which helps the patients. Dose-painting approach need to be evaluated. 
Objective: To evaluate the DCP technique in the case of boosting the DILs by radiobiological parameters, tumor control probability (TCP), and normal tissue complication probability (NTCP) via PET/CT images traced by 68Ga-PSMA.
Material and Methods: In this analytical study, 68Ga-PSMA PET/CT images were obtained from patients with DILs that were delineated using the Fuzzy c-mean (FCM) algorithm and thresholding methods. The protocol of therapy included two phases; at the first phase (ph1), a total dose of 72 Gy in 36 fractions were delivered to the planning target volume (PTV1); the seconds phase consisted of the application of variable doses to the PTV2. Moreover, two concepts were also considered to calculate the TCP using the Zaider-Minerbo model. 
Results: The lowest volume in DILs belonged to the DIL1 extracted by the FCM method. According to dose-volume parameters of the rectum and bladder, by the increase in the PTV dose higher than 92 Gy, the amounts of rectum and bladder doses are increased. There was no difference between the TCPs of DILs at doses higher than 86 Gy and 100 Gy for ordinary and high clone density, respectively.  
Conclusion: Consequently, our dose-painting approach for DILs, extracted by the FCM method via PET/CT images, can reduce the total dose for prostate radiation with 100% tumor control and less normal tissue complications.
کلیدواژه‌ها
Dose-Response Relationship, Radiation؛ Prostate؛ Positron-Emission Tomography
سایر فایل های مرتبط با مقاله
مراجع
  1. Cooper CS, Eeles R, Wedge DC, Van Loo P, Gundem G, Alexandrov LB, Kremeyer B, et al. Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics. 2015;47(4):367-72. doi: 10.1038/ng.3221. PubMed PMID: 25730763. PubMed PMCID: PMC4380509.
  2. Wang T, Press RH, Giles M, Jani AB, Rossi P, Lei Y, Curran WJ, Patel P, Liu T, Yang X. Multiparametric MRI-guided dose boost to dominant intraprostatic lesions in CT-based High-dose-rate prostate brachytherapy. The British Journal of Radiology. 2019;92(1097):20190089. doi: 10.1259/bjr.20190089. PubMed PMID: 30912959. PubMed PMCID: PMC6580917.
  3. Uzan J, Nahum AE, Syndikus I. Prostate dose-painting radiotherapy and radiobiological guided optimisation enhances the therapeutic ratio. Clinical Oncology. 2016;28(3):165-70. doi: 10.1016/j.clon.2015.09.006. PubMed PMID: 26482453.
  4. Bentzen SM. Theragnostic imaging for radiation oncology: dose-painting by numbers. The Lancet Oncology. 2005;6(2):112-7. doi: 10.1016/S1470-2045(05)01737-7. PubMed PMID: 15683820.
  5. Cattaneo GM, Bettinardi V, Mapelli P, Picchio M. PET guidance in prostate cancer radiotherapy: Quantitative imaging to predict response and guide treatment. Physica Medica. 2016;32(3):452-8. doi: 10.1016/j.ejmp.2016.02.013. PubMed PMID: 27080346.
  6. Erdi YE, Mawlawi O, Larson SM, Imbriaco M, Yeung H, Finn R, Humm JL. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997;80(12 Suppl):2505-9. doi: 10.1002/(sici)1097-0142(19971215)80:12+<2505::aid-cncr24>3.3.co;2-b. PubMed PMID: 9406703.
  7. Hatt M, Le Rest CC, Turzo A, Roux C, Visvikis D. A fuzzy locally adaptive Bayesian segmentation approach for volume determination in PET. IEEE Trans Med Imaging. 2009;28(6):881-93. doi: 10.1109/TMI.2008.2012036. PubMed PMID: 19150782. PubMed PMCID: PMC2912931.
  8. Zamboglou C, Klein CM, Thomann B, Fassbender TF, Rischke HC, Kirste S, Henne K, et al. The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer. Radiat Oncol. 2018;13(1):65. doi: 10.1186/s13014-018-1014-1. PubMed PMID: 29650029. PubMed PMCID: PMC5898009.
  9. Akhter W, Khan M, Karim O, Motiwala H, Laniado M. PE59: Early experience with the MIM symphony software registration for MRI-targeted transperineal prostate biopsies. European Urology Supplements. 2014;13(3):38. doi: 10.1016/S1569-9056(14)50090-5.
  10. Chang JH, Gehrke C, Prabhakar R, Gill S, Wada M, Joon DL, Khoo V. RADBIOMOD: a simple program for utilising biological modelling in radiotherapy plan evaluation. Physica Medica. 2016;32(1):248-54. doi: 10.1016/j.ejmp.2015.10.091. PubMed PMID: 26549777.
  11. Cellini N, Morganti AG, Mattiucci GC, Valentini V, Leone M, Luzi S, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys. 2002;53(3):595-9. doi: 10.1016/s0360-3016(02)02795-5. PubMed PMID: 12062602.
  12. Komek H, Can C, Yilmaz U, Altindag S. Prognostic value of 68 Ga PSMA I&T PET/CT SUV parameters on survival outcome in advanced prostat cancer. Ann Nucl Med. 2018;32(8):542-52. doi: 10.1007/s12149-018-1277-5. PubMed PMID: 30006752.
  13. Bouchelouche K, Oehr P. Recent developments in urologic oncology: positron emission tomography molecular imaging. Curr Opin Oncol. 2008;20(3):321-6. doi: 10.1097/CCO.0b013e3282f8b02b. PubMed PMID: 18391633.
  14. Wang H, Vees H, Miralbell R, Wissmeyer M, Steiner C, Ratib O, Senthamizhchelvan S, Zaidi H. 18F-fluorocholine PET-guided target volume delineation techniques for partial prostate re-irradiation in local recurrent prostate cancer. Radiother Oncol. 2009;93(2):220-5. doi: 10.1016/j.radonc.2009.08.037. PubMed PMID: 19767115.
  15. Pathmanathan AU, Alexander EJ, Huddart RA, Tree AC. The delineation of intraprostatic boost regions for radiotherapy using multimodality imaging. Future Oncol. 2016;12(21):2495-511. doi: 10.2217/fon-2016-0129. PubMed PMID: 27322113.
  16. Azzeroni R, Maggio A, Fiorino C, Mangili P, Cozzarini C, De Cobelli F, Di Muzio NG, Calandrino R. Biological optimization of simultaneous boost on intra-prostatic lesions (DILs): Sensitivity to TCP parameters. Phys Med. 2013;29(6):592-8. doi: 10.1016/j.ejmp.2012.10.002. PubMed PMID: 23103321.
  17. Ruggieri R, Naccarato S, Nahum AE. Severe hypofractionation: non-homogeneous tumour dose delivery can counteract tumour hypoxia. Acta Oncol. 2010;49(8):1304-14. doi: 10.3109/0284186X.2010.486796. PubMed PMID: 20500031.
  18. Buettner F, Gulliford SL, Webb S, Sydes MR, Dearnaley DP, Partridge M. The dose–response of the anal sphincter region–an analysis of data from the MRC RT01 trial. Radiother Oncol. 2012;103(3):347-52. doi: 10.1016/j.radonc.2012.03.002. PubMed PMID: 22520267.
  19. Klayton T, Price R, Buyyounouski MK, Sobczak M, Greenberg R, Li J, Keller L, Sopka D, Kutikov A, Horwitz EM. Prostate bed motion during intensity-modulated radiotherapy treatment. Int J Radiat Oncol Biol Phys. 2012;84(1):130-6. doi: 10.1016/j.ijrobp.2011.11.041. PubMed PMID: 22330987. PubMed PMCID: PMC3285397.
  20. Bauman G, Haider M, Van der Heide UA, Ménard C. Boosting imaging defined dominant prostatic tumors: a systematic review. Radiother Oncol. 2013;107(3):274-81. doi: 10.1016/j.radonc.2013.04.027. PubMed PMID: 23791306.
  21. Niyazi M, Bartenstein P, Belka C, Ganswindt U. Choline PET based dose-painting in prostate cancer-Modelling of dose effects. Radiat Oncol. 2010;5:23. doi: 10.1186/1748-717X-5-23. PubMed PMID: 20298546. PubMed PMCID: PMC2848061.
آمار
تعداد مشاهده مقاله: 1,796
تعداد دریافت فایل اصل مقاله: 273


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب